Archeon raises $9m for EOlife clinical expansion

Archeon Medical has raised $9 million (€7.5 million) to expand clinical validation and commercial deployment of EOlife, its electronic feedback system for monitoring manual ventilation during cardiac arrest resuscitation.

The Series A round was led by Newfund through its HEKA fund, with participation from funds managed by Eiffel Investment Group and UI Investissement alongside existing investors Majycc Innovation Santé and Karot Capital. Archeon plans to use the financing for studies involving more than 1,500 cardiac arrest patients across Europe and the US.

EOlife sits in the manual ventilation circuit between the ventilation source and the patient interface. Its single use FlowSens digital flow sensor measures gas moving through the circuit, while the reusable electronic unit converts those measurements into live information that can guide ventilation during resuscitation.

The system calculates parameters including insufflated volume, tidal volume, ventilation frequency and leakage. Displaying those values during use gives the operator direct information about the ventilation being delivered instead of relying only on bag compression, chest movement or an estimate of the seal around the patient interface.

Insufflated volume and tidal volume can differ because not all gas pushed through the bag necessarily reaches and leaves the lungs. Leakage may occur around a mask or elsewhere in the circuit, so measuring both inspiratory and expiratory flow gives the system information from which it can estimate delivered volume and identify excessive loss.

EOlife supports continuous ventilation and 30:2 resuscitation modes, with feedback linked to the selected patient height. Visual guidance indicates when measured ventilation parameters move outside the configured range, allowing the technique to be adjusted while compressions and ventilation continue.

FlowSens is designed as a single use component because it sits directly in the ventilation path, while the EOlife electronics are reusable. Archeon specifies a minimum operating time of five hours, a replaceable external battery and IP44 protection against splashing water and ingress of solid objects above the defined size.

Manual ventilation can vary with operator force, rate, mask seal and the patient’s airway conditions, and those variables may change during transport or a prolonged resuscitation. The electronics cannot remove that variability, but they can convert airflow into repeatable measurements that show how the delivered ventilation changes from one cycle to the next.

Clinical benefit depends on more than whether the sensor can measure flow accurately. The feedback has to be understood and acted on under emergency care conditions, which is why Archeon is expanding testing across different responders, patients and treatment settings rather than relying on engineering performance or simulation alone.

The planned programme includes Amsterdam UMC in the Netherlands and US work involving Tualatin Valley Fire & Rescue in Oregon and Rush University Medical Center in Chicago. Archeon expects results from the Tualatin Valley study in the first quarter of 2027, while the Rush programme runs on a longer timetable.

Earlier observational work found an association between EOlife use and improved survival with favourable neurological outcomes. Because observational studies cannot establish that the device itself caused the difference, the larger clinical programme is intended to provide stronger evidence across a broader group of patients and operators.

Medical electronics are increasingly being placed inside the procedure rather than used only for diagnosis before or after it. Mendaera has integrated semiconductor ultrasound imaging into its Focalist robotic platform, where live sensing also informs an intervention while it is being performed.

EOlife is already used in clinical and training settings, so the financing is directed at a larger evidence base and wider commercial deployment rather than development of a first prototype. The core electronic task remains tightly defined: measure respiratory flow quickly enough to provide useful volume, rate and leakage information while manual ventilation is under way.

The planned studies will test whether that measurement and feedback remain useful when the device moves across a much larger set of emergency care environments. Their results will matter more than incremental changes to the display or enclosure because they will show whether the existing sensing architecture produces consistent benefits when operators and patient conditions vary.